109 related articles for article (PubMed ID: 22027750)
1. Identification of cervical cancer proteins associated with treatment with paclitaxel and cisplatin in patients.
Liu H; Han Y; Mi R; Zhang Y; Su G; Wang H; Zhou X; Liu X; Zhu B
Int J Gynecol Cancer; 2011 Nov; 21(8):1452-7. PubMed ID: 22027750
[TBL] [Abstract][Full Text] [Related]
2. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
3. Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer.
Zou S; Shen Q; Hua Y; Jiang W; Zhang W; Zhu X
Reprod Sci; 2013 Nov; 20(11):1356-64. PubMed ID: 23599374
[TBL] [Abstract][Full Text] [Related]
4. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients.
Bae SM; Lee CH; Cho YL; Nam KH; Kim YW; Kim CK; Han BD; Lee YJ; Chun HJ; Ahn WS
Gynecol Oncol; 2005 Oct; 99(1):26-35. PubMed ID: 16051329
[TBL] [Abstract][Full Text] [Related]
5. Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT.
Zhu H; Tao X; Zhou L; Sheng B; Zhu X; Zhu X
BMC Cancer; 2019 Aug; 19(1):865. PubMed ID: 31470801
[TBL] [Abstract][Full Text] [Related]
6. Proteomic identification of differentially-expressed proteins in squamous cervical cancer.
Zhu X; Lv J; Yu L; Zhu X; Wu J; Zou S; Jiang S
Gynecol Oncol; 2009 Jan; 112(1):248-56. PubMed ID: 19007971
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy.
Garzetti GG; Ciavattini A; Provinciali M; Di Stefano G; Lucarini G; Goteri G; Biagini G
Anticancer Res; 1996; 16(5B):3229-34. PubMed ID: 8920796
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells.
Lee KH; Yim EK; Kim CJ; Namkoong SE; Um SJ; Park JS
Gynecol Oncol; 2005 Jul; 98(1):45-53. PubMed ID: 15907983
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
[TBL] [Abstract][Full Text] [Related]
10. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells.
Yim EK; Lee KH; Kim CJ; Park JS
Int J Gynecol Cancer; 2006; 16(2):690-7. PubMed ID: 16681749
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
12. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma.
Zhu H; Pei HP; Zeng S; Chen J; Shen LF; Zhong MZ; Yao RJ; Shen H
J Proteome Res; 2009 Aug; 8(8):3969-76. PubMed ID: 19507834
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
14. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Hosaka M; Watari H; Kato T; Odagiri T; Konno Y; Endo D; Mitamura T; Kikawa S; Suzuki Y; Sakuragi N
J Surg Oncol; 2012 May; 105(6):612-6. PubMed ID: 22065519
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
17. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
[TBL] [Abstract][Full Text] [Related]
18. [Proteomic study of paclitaxel on human cervical carcinoma HCE1].
Cao LQ; Lin QH; Li X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jun; 33(6):512-7. PubMed ID: 18599999
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results.
Park DC; Suh MJ; Yeo SG
Int J Gynecol Cancer; 2009 Jul; 19(5):943-7. PubMed ID: 19574789
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
